These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 21509439)

  • 21. Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS.
    Wu L; Li X; Su J; He Q; Zhang X; Chang C; Pu Q
    J Cancer Res Clin Oncol; 2011 Oct; 137(10):1563-9. PubMed ID: 21845438
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Homoharringtonine in combination with cytarabine and aclarubicin in the treatment of refractory/relapsed acute myeloid leukemia: a single-center experience.
    Yu W; Mao L; Qian J; Qian W; Meng H; Mai W; Tong H; Tong Y; Jin J
    Ann Hematol; 2013 Aug; 92(8):1091-100. PubMed ID: 23595277
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia.
    Jin J; Jiang DZ; Mai WY; Meng HT; Qian WB; Tong HY; Huang J; Mao LP; Tong Y; Wang L; Chen ZM; Xu WL
    Leukemia; 2006 Aug; 20(8):1361-7. PubMed ID: 16791270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of efficacy of HCAG and CAG re-induction chemotherapy in elderly low- and intermediate-risk group patients diagnosed with acute myeloid leukemia.
    Zhang JY; Li L; Liu W; Jin Y; Zhao M; Zhou Y; Fan Z
    Clin Transl Oncol; 2021 Jan; 23(1):48-57. PubMed ID: 32458310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Using low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor in a priming induction therapy for acute myeloid leukemia: a retrospective study of 29 cases in china.
    Liu H; Zhang J; Ren S; Chen M; Liu L; Zhang H
    Leuk Lymphoma; 2017 Nov; 58(11):2758-2761. PubMed ID: 28406352
    [No Abstract]   [Full Text] [Related]  

  • 26. A phase II study of Homoharringtonine for the treatment of children with refractory or recurrent acute myelogenous leukemia: a pediatric oncology group study.
    Bell BA; Chang MN; Weinstein HJ
    Med Pediatr Oncol; 2001 Aug; 37(2):103-7. PubMed ID: 11496347
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prognostic significance of leukemic cells clearance kinetics evaluation during the initial course of induction therapy with HAD (homoharringtonine, cytosine arabinoside, daunorubicin) in patients with de novo acute myeloid leukemia.
    Xiao Z; Xue H; Li R; Zhang L; Yu M; Hao Y
    Am J Hematol; 2008 Mar; 83(3):203-5. PubMed ID: 17874451
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804.
    Stone RM; Donohue KA; Stock W; Hars V; Linker CA; Shea T; Deangelo DJ; Marcucci G; Bloomfield CD; Larson RA;
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):859-64. PubMed ID: 18670778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype.
    Mi Y; Xue Y; Yu W; Liu S; Zhao Y; Meng Q; Bian S; Wang J
    Leuk Lymphoma; 2008 Mar; 49(3):524-30. PubMed ID: 18297530
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Homoharringtonine, aclarubicin and cytarabine (HAA) regimen as the first course of induction therapy is highly effective for acute myeloid leukemia with t (8;21).
    Zhu HH; Jiang H; Jiang Q; Jia JS; Qin YZ; Huang XJ
    Leuk Res; 2016 May; 44():40-4. PubMed ID: 26994850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia.
    Zhang WG; Wang FX; Chen YX; Cao XM; He AL; Liu J; Ma XR; Zhao WH; Liu SH; Wang JL
    Am J Hematol; 2008 Mar; 83(3):185-8. PubMed ID: 17899614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study.
    van Eijkelenburg NKA; Rasche M; Ghazaly E; Dworzak MN; Klingebiel T; Rossig C; Leverger G; Stary J; De Bont ESJM; Chitu DA; Bertrand Y; Brethon B; Strahm B; van der Sluis IM; Kaspers GJL; Reinhardt D; Zwaan CM
    Haematologica; 2018 Sep; 103(9):1484-1492. PubMed ID: 29773602
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia.
    Kantarjian HM; Talpaz M; Smith TL; Cortes J; Giles FJ; Rios MB; Mallard S; Gajewski J; Murgo A; Cheson B; O'Brien S
    J Clin Oncol; 2000 Oct; 18(20):3513-21. PubMed ID: 11032593
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor for elderly patients with de novo acute myeloid leukemia.
    Chen C; Xu W; Yang J
    Leuk Lymphoma; 2015 Jan; 56(1):141-6. PubMed ID: 24724783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute myeloid leukemia in Manitoba. The consequences of standard "7 + 3" remission-induction therapy followed by high dose cytarabine postremission consolidation for myelosuppression, infectious morbidity, and outcome.
    Bow EJ; Kilpatrick MG; Scott BA; Clinch JJ; Cheang MS
    Cancer; 1994 Jul; 74(1):52-60. PubMed ID: 8004583
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients.
    Röllig C; Kramer M; Gabrecht M; Hänel M; Herbst R; Kaiser U; Schmitz N; Kullmer J; Fetscher S; Link H; Mantovani-Löffler L; Krümpelmann U; Neuhaus T; Heits F; Einsele H; Ritter B; Bornhäuser M; Schetelig J; Thiede C; Mohr B; Schaich M; Platzbecker U; Schäfer-Eckart K; Krämer A; Berdel WE; Serve H; Ehninger G; Schuler US;
    Ann Oncol; 2018 Apr; 29(4):973-978. PubMed ID: 29390048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
    Hołowiecki J; Grosicki S; Kyrcz-Krzemien S; Skotnicki AB; Piatkowska-Jakubas B; Warzocha K; Seferynska I; Zdziarska B
    Ann Hematol; 2008 May; 87(5):361-7. PubMed ID: 18074133
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outpatient ADE (cytarabine, daunorubicin, and etoposide) is feasible and effective for the first relapse of pediatric acute myeloid leukemia: A prospective, phase II study.
    Garg A; Ganguly S; Vishnubhatla S; Chopra A; Bakhshi S
    Pediatr Blood Cancer; 2020 Sep; 67(9):e28404. PubMed ID: 32672904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intensive timed sequential remission induction chemotherapy with high-dose cytarabine for childhood acute myeloid leukemia.
    Loeb DM; Bowers DC; Civin CI; Friedman AD
    Med Pediatr Oncol; 2001 Oct; 37(4):365-71. PubMed ID: 11568900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome.
    Kojima S; Sako M; Kato K; Hosoi G; Sato T; Ohara A; Koike K; Okimoto Y; Nishimura S; Akiyama Y; Yoshikawa T; Ishii E; Okamura J; Yazaki M; Hayashi Y; Eguchi M; Tsukimoto I; Ueda K
    Leukemia; 2000 May; 14(5):786-91. PubMed ID: 10803507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.